# Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer

> **NCT05761977** · — · UNKNOWN · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 50 (estimated)

## Conditions studied

- Small-cell Lung Cancer
- Extensive-stage Small-cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05761977
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-31
- **Primary completion:** 2023-04
- **Final completion:** 2024-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05761977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05761977, "Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05761977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*